• Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact
Contact Icon Contact Icon Contact Icon
  • Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact
  • Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact

Our Products

For Pulmonary Hypertension

TNX-201 (oral enteric coated imatinib)
in PAH

  • Imatinib already proven effective for PAH in a Phase 3 trial
  • Novel oral formulation development to mitigate previous problem of gastric intolerance
  • FDA Agreement for our improved, enriched trial design requiring fewer patients
  • Potential first disease-modifying drug for PAH
TNX-103 (oral levosimendan)
in PH-HFpEF

  • Levosimendan approved safe and effective for acute decompensated heart failure in 60+ countries since 2000
  • Intravenous levosimendan first treatment to show efficacy in PH-HFpEF in the Tenax Phase 2 trial
  • FDA agreement to use oral levosimendan formulation in Phase 3 development program
  • Discovery of levosimendan’s novel mechanism of action and treatment target makes it uniquely effective for HFpEF patients

TNX-201 (oral enteric coated imatinib)

in PAH

LEARN MORE BELOW


DISEASE:
PAH
UNMET NEED
MECHANISM
OF ACTION
CLINICAL
DEVELOPMENT

TNX-103 (oral levosimendan)

in PH-HFpEF

LEARN MORE BELOW


DISEASE:
PH-HFpEF
UNMET NEED
MECHANISM
OF ACTION
CLINICAL
DEVELOPMENT
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Contact
    • Email

Tenax Therapeutics

Specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension.

Contact Icon Contact Icon Contact Icon

© Copyright 2023 Tenax Therapeutics. All Rights Reserved.
Site created by Top Shelf Design

  • Privacy Policy
  • Terms of Service